Chemotherapy induced diarrhea

Journal of Oncology Pharmacy Practice

Volumn 13, Issue 4, 2007, Pages 181-198

  Richardson, Gillian ^a   Dobish, Roxanne ^b,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

^c BscPharm   (Canada)

Author keywords

Chemotherapy; Diarrhea; Guidelines; Irinotecan; Loperamide; Octreotide

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACETORPHAN; ACTIVATED CARBON; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ATROPINE; BUDESONIDE; CAPECITABINE; CEFIXIME; CEFTRIAXONE; CELECOXIB; CIPROFLOXACIN; DIPHENOXYLATE; FLUOROURACIL; FOLINIC ACID; GLUTAMINE; IRINOTECAN; ISPAGULA; LOPERAMIDE; METRONIDAZOLE; NEOMYCIN; OCTREOTIDE; OPIATE; PENICILLIN G; PLACEBO; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; BLOATING; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COCHRANE LIBRARY; COST EFFECTIVENESS ANALYSIS; DEHYDRATION; DIAPHORESIS; DIARRHEA; DIET THERAPY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HYDROLYSIS; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; EMBASE; ENTEROPATHY; EVENING DOSAGE; FLUID THERAPY; FLUSHING; GASTROINTESTINAL INFECTION; GASTROINTESTINAL TOXICITY; HEALTH CARE COST; HEREDITY; HUMAN; HYPERSALIVATION; INCIDENCE; INFORMATION RETRIEVAL; LACRIMATION DISORDER; MEDLINE; MIOSIS; MORBIDITY; MORTALITY; NEOPLASM; NEUTROPENIA; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REHYDRATION; REVIEW; RHINITIS; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ANTIDIARRHEALS; ANTINEOPLASTIC AGENTS; DIARRHEA; HUMANS; NEOPLASMS; PHARMACISTS; PRACTICE GUIDELINES AS TOPIC; PROFESSIONAL ROLE; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 38449105148     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155207077335     Document Type: Review

References (78)

1. Arnold RJG, Gabrail N, Raut M, Kim R, Sung JCY, Zhou Y. Clinical implications of chemotherapy-induced diarrhea. J Support Oncol 2005; 3: 227-32.
2. Sharma R, Tobin P, Clarke SJ. Management of chemotherapy-induced nausea vomiting, oral mucositis and diarrhea. Lancet Oncol 2005; 6: 93-102.
3. Arbuckle RB, Huber SL, Zacker C. The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study. Oncologist 2000; 5: 250-59.
4. Kornblau S, Benson AB, III, Catalano R et al. Management of cancer treatment-related diarrhea: Issues and therapeutic strategies. J Pain Symptom Manage 2000; 19: 118-29.
5. Gastrointestinal Complications - Diarrhea. National Cancer Institute. Available at: http://www.cancer.gov/cancertopics/pdq/ supportivecare/gastrointestinalcomplications/healthprofessional/page5. Accessed May 19, 2006.
6. Rosenoff S. Resolution of refractory chemotherapy induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies. Support Care Cancer 2004; 12: 561-70.
7. Saltz LB. Understanding and managing chemotherapy-induced diarrhea. J Support Oncol 2003; 1: 35-46.
8. Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0. National Cancer Institute, Bethesda; National Institutes of Health, U.S. Department of Health and Human Services. April 30, 1999.
9. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Effects, Version 3.0. National Cancer Institute, Bethesda; National Institutes of Health, U.S. Department of Health and Human Services. December 12, 2003.
10. Walder S. Treatment guidelines for chemotherapy-induced diarrhea. Oncology Special Edition (McMahon Med) 2005; 8: 105-10.
11. Mercadante S. Diarrhea in terminally ill patients: Pathophysiology and treatment. J Pain Symptom Manage 1995; 10: 298-309.
12. Field M. Intestinal ion transport and the pathophysiology of diarrhea. J Clin Invest 2003; 111: 931-43.
13. Forrester A. Diarrhea. In Repchinsky C, Leblanc C, Jovalsas B, Leahey K, Way C. eds. Patient Self Care. Ottawa, Ontario, Canadian Pharmacists Association, 2002: 238-50.
14. Diskin A. Gastroenteritis. eMedicine (from WebMD). February 28, 2006. Available at: http://www.emedicine.com/EMERG/topic213.htm. Accessed May 18, 2006.
15. Yang X, Hu Z, Chan SY et al. Novel agents that potentially inhibit irinotecan-induced diarrhea. Curr Med Chem 2005; 12: 1343-58.
16. Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 2002; 13: 1841-51.
17. Innocenti F, Iyer L, Ratain MJ. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab Dispos 2001; 29: 596-600.
18. Ikegami T, Ha L, Arimori K et al. Intestinal alkalization as a possible preventative mechanism in irinotecan (CPT-11)-induced diarrhea. Cancer Res 2002; 62: 179-87.
19. Alimonti A, Gelibter A, Pavese I et al. New approaches to prevent intestinal toxicity of irinotecan-based regimens. Cancer Treat Rev 2004; 30: 555-62.
20. Bengt G. Benefit-risk assessment of irinotecan in advanced colorectal cancer. Drug Saf 2005; 28: 417-33.
21. Crews KR. Individualizing chemotherapeutic treatment of colorectal cancer. Am J Health-Syst Pharm 2006; 63: S12-S17.
22. Borner MM, Bernhard J, Dietrich D et al. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality of life and toxicity. Ann Oncol 2005; 16: 282-88.
23. Barbounis V, Koumakis G, Vassilomanolakis M, Demiri M, Efremidis AP. Control of irinotecan-induced diarrhea by octreotide after loperamide failure. Support Care Cancer 2001; 9: 258-60.
24. Earle CC, Kwok A, Gazelle GS, Fuchs CS. Two schedules of second-line irinotecan for metastatic colon carcinoma. Cancer 2004; 101: 2533-39.
25. Rothenberg ML. Efficacy and toxicity of irinotecan in patients with colorectal cancer. Semin Oncol 1998; 25: 39-46.
26. Shah A. BCCA Guidelines on chemotherapy-induced diarrhea. October 13, 2004. In de Lemos ML, ed. BC Cancer Agency Cancer Drug Manual. Vancouver, British Columbia: BC Cancer Agency. Available at: http://www.bccancer.bc.ca/NR/rdonlyres/4E7EF86A-EAA5-4F3C-B147- B2512799F6B3/7371/GuidelinesforManagementofCID.pdf. Accessed May 25, 2006.
27. Michael M, Brittain M, Nagai J et al. Phase II study of activated charcoal to prevent irinotecan induced diarrhea. J Clin Oncol 2004; 22: 4410-17.
28. Diarrhea and Constipation (Chapter 27). The Merck Manual of Diagnosis and Therapy. Available at: http://www.merck.com/mrkshared/mmanual/ section3/chapter27/27b.jsp. Accessed July 10, 2006.
29. Viele CS. Overview of chemotherapy induced diarrhea. Semin Oncol Nurs 2003; 19: 2-5.
30. Saliba F, Hagipantelli R, Misset JL et al. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol 1998; 16: 2745-51.
31. Govindarajan R, Heaton KM, Broadwater R, Zeitlin A, Lang NP, Hauer-Jensen M. Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet 2000; 356: 566-67.
32. Dodds HM, Rivory LP. The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11). Mol Pharmacol 1999; 56: 1346-53.
33. Trifan OC, Durham WF, Salazar VS et al. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 2002; 62: 5778-84.
34. Rougier P, Bugat R, Douillard JY et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 251-60.
35. Camptosar (Product monograph). Pfizer Canada Inc. April 13, 2006. Available at: http://www.pfizer.ca/english/our%20products/ prescription%20pharmaceuticals/default.asp?s=1. Accessed June 13, 2006.
36. Irinotecan (Drug monograph). May 2006. In de Lemos ML, ed. BC Cancer Agency Cancer Drug Manual. Vancouver, British Columbia: BC Cancer Agency. Available at: http://www.bccancer.bc.ca/NR/rdonlyres/ 777153D1-62E3-49B7-838A-O6A031117E60/15966/ Irinotecanmonograph_1May06_revl.pdf. Accessed May 30, 2006.
37. Yumuk PF, Aydin SZ, Dane F et al. The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients. Int J Colorectal Dis 2004; 19: 609-10.
38. Von Hoff DD, Rothenberg ML, Pitot HC, et al. Irinotecan (CPT-11) therapy for patients with previously treated metastatic colorectal cancer (CRC): Overall results of FDA-reviewed pivotal US clinical trials. Proc Am Soc Clin Oncol 1997; 16: 228a (abstract 803).
39. Brandi G, Dabard J, Raibaud P et al. Intestinal microflora and digestive toxicity of irinotecan in mice. Clin Cancer Res 2006; 12: 1299-1307.
40. Chowbay B, Sharma A, Zhou Q, Cheung YB, Lee EJD. The modulation of irinotecan-induced diarrheao and pharmacokinetics by three different classes of pharmacological agents. Oncol Rep 2003; 10: 745-51.
41. Furman WL, Crews KR, Billups C et al. Cefixime allows greater dose escalation of oral irinotecan: a phase 1 study in pediatric patients with refractory solid tumors. J Clin Oncol 2006; 24: 563-70.
42. Mori K, Kondo T, Kamiyama Y, Kano Y, Tominaga K. Preventative effect of Kampo medicine (Haneshashin-to) against irinotecan-induced diarrhea in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2003; 51: 403-6.
43. Pan C, Loehrer P, Seitz D et al. A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first line therapy for advanced colorectal cancer. Oncology 2005; 69: 63-70.
44. Benson AB, III, Ajani JA, Catalano RB et al. Recommended guidelines for the treatment of cancer-treatment induced diarrhea. J Clin Oncol 2004; 22: 2918-26.
45. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 2001; 19: 3801-07.
46. von Bultzingslowen I, Adlerberth I, Wold AE, Dahlen G, Jontell M. Oral and intestinal microflora in 5-fluorouracil treated rats, translocation to cervical and mesenteric lymphnodes and effects of probiotic bacteria. Oral Microbiol Immunol 2003; 18: 278-84.
47. Jansman FGA, Sleijfer DT, de Graaf JC, Coenen JLLM, Brouwers JRBJ. Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. Drug Saf 2001; 24: 353-67.
48. Irinotecan (Drug monograph). Cancer Care Ontario. Available at: http://www.cancercare.on/pdfdrugs/irinot.pdf. Accessed May 30, 2006.
49. BCCA protocol summary for palliative therapy of advanced colorectal cancer using leucovorin and fluorouracil. British Columbia Cancer Center. Available at: http://www.bccancer.bc.ca/NR/rdonlyres/ COA8933B-3AAD-4EBA-A95C-4552AOA060C9/14326/GIFUFA_1mar2006.pdf. Accessed June 30, 2006.
50. Diarrhea. American Cancer Society. Available at: http://www.cancer.org/docroot/MBC/content/ MBC_2_3X_Diarrhea.asp?sitearea=MBC. Accessed July 11, 2006.
51. e-CPS. Canadian Pharmacists Association. Available at: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm. Accessed July 4, 2006.
52. Major P, Figueredo A, Tandan V et al. Role of octreotide in the management of patients with cancer. Curr Oncol 2003; 10: 161-79.
53. Rosenoff SH. Octreotide LAR resolves severe chemotherapy-induced diarrhea (CID) and allows continuation of full-dose therapy. Eur J Cancer Care 2004; 13: 380-83.
54. Karthaus M, Ballo H, Abenhardt W et al. Prospective, double blind, placebo controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer. Oncology 2005; 68: 326-32.
55. Deodorized tincture of opium. American Cancer Society. Available at: http://www.cancer.org/docroot/CDG/content/ CDG_deodorized_tincture_of_opium.asp Accessed December 28, 2006.
56. Ulbricht C, Basch E, eds. Psyllium. Natural Standard [database online]. Link from the University of Alberta Library. Available at: http://www.naturalstandard.com.login.ezproxy.library.ualberta.cal. Accessed March 13, 2007.
57. Ulbricht C, Basch E, eds. Lactobacillus acidophilus. Natural Standard [database online]. Link from the University of Alberta Library. Available at: http://www.naturalstandard.com.login.ezproxy.library.ualberta.ca/ Accessed December 27, 2006.
58. Wang HH, Shieh MJ, Liao KF. A blind, randomized comparison of racecadotril and loperamide for stopping acute diarrhea in adults. World J Gastroenterol 2005; 11: 1540-43.
59. Lecomte JM. An overview of clinical studies with racecadotril in adults. Int J Antimicrob Agents 2000; 14: 81-87.
60. Prado D. A multinational comparison of racecadotril and loperamide in the treatment of acute watery diarrhoea in adults. Scand J Gastroenterol 2002; 37: 656-61.
61. Daniele B, Perrone F, Gallo C et al. Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double bind, placebo controlled randomized trial. Gut 2001; 48: 28-33.
62. Study of Glutamine as Prophylaxis for Irinotecan Induced Diarrhea. Clinical trial sponsored by the Alberta Cancer Board. Available at: http://www.clinicaltrials.gov/ct/show/ NCT00255229;jsessionid=25C18C79C872C1A7D9C827A4861C8D1D?order=43. Accessed June 30, 2006.
63. Reardon DA, Qiunn JA, Vredenburgh J et al. Phase II Trial of Irinotecan plus Celecoxib in Adults with Recurrent Malignant Glioma. Cancer 2005; 103: 329-38.
64. Kehrer DFS, Sparreboom A, Verweij J et al. Modualtion of Irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 2001; 7: 1136-41.
65. Takeda Y, Tsuduki E, Izumi S et al. A phase I/II trial of irinotecan-cisplatin combined with anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-call lung cancer. Br J Cancer 2005; 93: 1341-49.
66. Personal communication. Health Canada Special Access Program (December 21, 2006).
67. Shinohara H, Killion JJ, Bucana CD, Yano CD, Fidler IJ. Oral administration of the immunomodulator JBT-3002 induces endogenous interleukin 15 in intestinal macrophages for protection against irinotecan-mediated destruction of intestinal epithelium. Clin Cancer Res 1999; 5: 2148-56.
68. Shinohara H, Bucana CD, Killion JJ, Fidler IJ. Intensified regression of colon cancer liver metastases in mice treated with irinotecan and the immunomodulator JBT 3002. J Immunother 2000; 23: 321-31.
69. Kuhn JG. Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report. Oncology (Huntingt) 2002; 16: 33-40.
70. Crews KR, Stewart CF, Jones-Wallace D et al. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res 2002; 8: 2202-09.
71. Manatsathit S, Dupont HL, Farthing M, Kositchaiwat C et al. Guideline for the management of acute diarrhea in adults. J Gastroenterol Hepatol 2002; 17: S54-S71.
72. Lee J. Pseudomembranous Colitis. eMedicine (from WebMD). July 1, 2005. Available at: http://www.emedicine.com/med/topic1942.htm. Accessed May 29, 2006.
73. Dranitsaris G, Maroun J, Shah A. Severe chemotherapy induced diarrhea in patients with colorectal cancer: A cost of illness analysis. Support Care Cancer 2005; 13: 318-24.
74. Wong AS, Lam CS, Tambyah PA. Fatal chemotherapy associated Clostridium difficile infection - a case report. Singapore Med J 2001; 42: 214-16.
75. Morales Chamorro R, Serrano Blanch R, Mendez Vidal MJ et al. Pseudomembranous colitis associated with chemotherapy with 5-fluorouracil [in Spanish; English Abstract]. Clin Transl Oncol 2005; 7: 258-61.
76. Blot E, Escande MC, Besson D et al. Outbreak of Clostridium difficile-related diarrhea in an adult oncology unit: risk factors and microbiological characteristics. J Hosp Infect 2003; 53: 187-92.
77. Kamthan AG, Bruckner HW, Hirschman SZ, Agus SG. Clostridium-difficile diarrhea induced by cancer-chemotherapy. Arch Intern Med 1992; 152: 1715-17.
78. Yokoyama T, Kondo H, Yokota T et al. Colonoscopy for frank bloody stools associated with cancer chemotherapy. Jpn J Clin Oncol 1997; 27: 111-14.